ClonOrgan

Focus: ClonOrgan is a biotechnology company focused on xenotransplantation, a frontier area addressing organ transplant shortages through animal-derived organ technologies. Based in Chengdu, China, the company operates in a highly specialized and emerging segment with significant regulatory complexity.

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About ClonOrgan

AI assessmentNot Hiring

No open roles listed right now. Follow ClonOrgan to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet.

Help build intelligence for ClonOrgan

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on xenotransplantation, a frontier biotech field with transformative potential for organ transplantation and massive unmet medical need
Early-stage company position offers equity upside and influence on company direction for those joining during formative phase
Located in Chengdu, China, providing access to growing biotech ecosystem and potential regulatory pathways in Asian markets

Watch Out For

No visible active hiring (0 open positions recorded), indicating company may not be actively recruiting or is in stealth/early stage with limited expansion
Significant data opacity—no public financial, funding, employee count, or clinical trial data available, making company stability and trajectory difficult to assess
Xenotransplantation faces major regulatory hurdles, reputational risks (animal welfare), and slow clinical validation timelines with uncertain commercial viability

Generated by Claude from ClonOrgan's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo